title: Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.
abstract: Sixteen patients with jaw biphosphonate-osteonecrosis and with exposed bone areas were subdivided into 2 treatment groups. The first group (7 patients) underwent superficial or radical surgical therapy, while the second (9 patients) underwent antibiotic treatment. A slight reduction of the necrotic areas was observed in 5 of 7 patients in the first group, whereas no change was observed in the remaining 2 patients at 22- and 24-month follow-up. A slight reduction of the necrotic areas was observed in 7 of 9 patients in the second group, whereas no change was observed in the remaining 2 patients at 5- and 24-month follow-up. The statistical analysis showed that the treatment regimen did not significantly influence the dimensional change in the exposed bone. The preliminary results seem to suggest that biphosphonate-associated osteonecrosis can be well controlled by a nonsurgical protocol consisting in long-term administration of antibiotics.
authors.affiliation: Department of Oral Science, University of Bologna, Bologna, Italy. lucio.montebugnoli@unibo.it
authors.forename: Lucio
authors.initials: L
authors.lastname: Montebugnoli
authors.forename: Laura
authors.initials: L
authors.lastname: Felicetti
authors.forename: Davide Bartolomeo
authors.initials: DB
authors.lastname: Gissi
authors.forename: Angelo
authors.initials: A
authors.lastname: Pizzigallo
authors.forename: Gian Andrea
authors.initials: GA
authors.lastname: Pelliccioni
authors.forename: Claudio
authors.initials: C
authors.lastname: Marchetti
mesh_terms: D000368:Aged; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use*; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects; D007571:Jaw Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000601:surgery; D016014:Linear Models; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced / Q000188:drug therapy* / Q000601:surgery; D000077268:Pamidronate; D011446:Prospective Studies; D000077211:Zoledronic Acid
chemical_list: D000900:Anti-Bacterial Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D008795:Metronidazole; D000077211:Zoledronic Acid; D019980:Amoxicillin-Potassium Clavulanate Combination; D000077268:Pamidronate